Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA [0.03%]
X连锁低磷血症患者布索马布治疗的美国临床应用评述及更正通知
Katherine A Lyseng-Williamson
Katherine A Lyseng-Williamson
[This corrects the article DOI: 10.1007/s40267-018-0560-9.].
Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA [0.03%]
对福司曲波苷用于慢性免疫性血小板减少症的校正：在美国的应用概要
Kate McKeage,Katherine A Lyseng-Williamson
Kate McKeage
[This corrects the article DOI: 10.1007/s40267-018-0551-x.].
Correction to: Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA [0.03%]
关于安侃塞特α在治疗阿哌沙班和利伐沙班相关急性大出血中的应用概况：对美国用药情况的分析校正文章
Young-A Heo
Young-A Heo
[This corrects the article DOI: 10.1007/s40267-018-0561-8.].
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use [0.03%]
卡博替尼作为晚期肾细胞癌一线治疗药物的使用概况
Katherine A Lyseng-Williamson
Katherine A Lyseng-Williamson
Oral cabozantinib tablets (Cabometyx®) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated i...
Osimertinib as first-line therapy in advanced NSCLC: a profile of its use [0.03%]
奥希替尼一线治疗晚期NSCLC：应用概览
Lesley J Scott
Lesley J Scott
Osimertinib (Tagrisso®) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced ...
Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use [0.03%]
银杏叶提取物EGb 761在轻至中度痴呆症对症治疗中的应用概况分析
Kate McKeage,Katherine A Lyseng-Williamson
Kate McKeage
EGb 761® (Tanakan®) is a standardized extract of Ginkgo biloba leaves that has demonstrated protective properties against neuronal and vascular damage. Overall, in randomized, placebo-controlled clinical trials and meta-analyses in adults...
Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use [0.03%]
用于慢性便秘对症治疗的非电解质型聚乙二醇4000(麦角醇4000)：用药概评
Katherine A Lyseng-Williamson
Katherine A Lyseng-Williamson
Macrogol 4000, a biologically inert, non-absorbable osmotic laxative, is a highly effective and well-tolerated first-line option for the treatment of the symptoms of chronic idiopathic/functional constipation in children and adults. High-mo...
Katherine A Lyseng-Williamson
Katherine A Lyseng-Williamson
The EU indication for anakinra has been extended to include Still's disease, a serious rare inflammatory disorder of unknown aetiology that comprises adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA). As a...
Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA [0.03%]
安格列特用于美国阿哌沙班和利伐沙班所致急性大出血治疗的概况分析报告
Young-A Heo
Young-A Heo
Andexanet alfa (Andexxa®), a first-in-class recombinant modified factor Xa protein, is currently the only specific agent available to reverse life-threatening or uncontrolled bleeding with the factor Xa inhibitors apixaban and rivaroxaban....
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA [0.03%]
布罗舒马斯特用于治疗X连锁低磷血症：在美国的药物概况分析报告
Katherine A Lyseng-Williamson
Katherine A Lyseng-Williamson
Burosumab (Crysvita®), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. It di...